Phathom Pharmaceuticals, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for PHAT, updated each market day.
PHAT AI Sentiment
AI sees no strong directional signal for Phathom Pharmaceuticals, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Phathom Pharmaceuticals, Inc. Common Stock
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Sector
Exchange
Market Cap
$1,003,996,678
Cap Tier
Employees
371
Headquarters
FLORHAM PARK, NJ
Listed Since
Oct. 25, 2019
Website
PHAT Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
PHAT Volatility
Phathom Pharmaceuticals, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
